Aquestive Therapeutics (AQST) Free Cash Flow (2017 - 2025)
Historic Free Cash Flow for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to -$12.9 million.
- Aquestive Therapeutics' Free Cash Flow fell 772.58% to -$12.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.9 million, marking a year-over-year decrease of 4821.37%. This contributed to the annual value of -$35.9 million for FY2024, which is 38702.37% down from last year.
- As of Q3 2025, Aquestive Therapeutics' Free Cash Flow stood at -$12.9 million, which was down 772.58% from -$8.0 million recorded in Q2 2025.
- Aquestive Therapeutics' 5-year Free Cash Flow high stood at $8.8 million for Q1 2023, and its period low was -$23.5 million during Q1 2025.
- In the last 5 years, Aquestive Therapeutics' Free Cash Flow had a median value of -$8.0 million in 2025 and averaged -$7.0 million.
- Per our database at Business Quant, Aquestive Therapeutics' Free Cash Flow surged by 19762.63% in 2022 and then tumbled by 37878.3% in 2024.
- Over the past 5 years, Aquestive Therapeutics' Free Cash Flow (Quarter) stood at -$8.6 million in 2021, then surged by 197.63% to $8.4 million in 2022, then plummeted by 159.09% to -$5.0 million in 2023, then plummeted by 31.18% to -$6.5 million in 2024, then crashed by 98.09% to -$12.9 million in 2025.
- Its last three reported values are -$12.9 million in Q3 2025, -$8.0 million for Q2 2025, and -$23.5 million during Q1 2025.